<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">adair</journal-id><journal-title-group><journal-title xml:lang="ru">Аллергология и Иммунология в Педиатрии</journal-title><trans-title-group xml:lang="en"><trans-title>Allergology and Immunology in Paediatrics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2500-1175</issn><issn pub-type="epub">2712-7958</issn><publisher><publisher-name>Ассоциация детских аллергологов и иммунологов России</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.53529/2500-1175-2023-4-31-39</article-id><article-id custom-type="elpub" pub-id-type="custom">adair-118</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Уровни циркулирующих цитокинов у детей с рассеянным склерозом при разной эффективности интерфероновой терапии</article-title><trans-title-group xml:lang="en"><trans-title>Levels of circulating cytokines in children with multiple sclerosis with different effectiveness of interferon therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4704-6885</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Радыгина</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Radygina</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Радыгина Татьяна Вячеславовна - к. м. н., старший научный сотрудник лаборатории экспериментальной иммунологии и вирусологии</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Tatiana Vyacheslavovna Radygina - PhD (Medicine), Senior Research Associate of Laboratory of Experimental Immunology and Virology</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">radigina.tv@nczd.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0896-6996</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петричук</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrichuk</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петричук Светлана Валентиновна - д. б. н., профессор, главный научный сотрудник лаборатории экспериментальной иммунологии и вирусологии</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Svetlana Valentinovna Petrichuk - PhD, MD (Biology), Professor, Chief Scientist of Laboratory of Experimental Immunology and Virology</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">cito@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9213-5281</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курбатова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurbatova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Курбатова Ольга Владимировна - к. м. н., старший научный сотрудник, и. о. заведующего лаборатории экспериментальной иммунологии и вирусологии</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Olga Vladimirovna Kurbatova - PhD (Medicine), Senior Research Associate, Head of Laboratory of Experimental Immunology and Virology</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">putintseva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7771-3314</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Купцова</surname><given-names>Д. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuptsova</surname><given-names>D. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Купцова Дарья Геннадьевна - младший научный сотрудник лаборатории экспериментальной иммунологии и вирусологии</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Daria Gennadievna Kuptsova - Junior Researcher of Laboratory of Experimental Immunology and Virology</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">dg.kuptsova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8586-7946</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фисенко</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Fisenko</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фисенко Андрей Петрович - д. м. н., профессор, директор</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Andrei Petrovich Fisenko - PhD, MD (Medicine), Professor, Head</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">fisenko@nczd.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8923-4652</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семикина</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Semikina</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Семикина Елена Леонидовна - д. м. н., главный научный сотрудник лаборатории экспериментальной иммунологии и вирусологии, заведующий лабораторным отделом</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Elena Leonidovna Semikina - PhD, MD (Medicine), Chief Scientist of Laboratory of Experimental Immunology and Virology, Head of Laboratory Department</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">semikinaelena@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5645-5181</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фрейдлин</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Freydlin</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фрейдлин Екатерина Валерьевна - лаборант-исследователь лаборатории экспериментальной иммунологии и вирусологии</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Ekaterina Valeryevna Freydlin - Research assistant of Laboratory of Experimental Immunology and Virology</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">frdl-cito@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1574-2050</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдуллаева</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdullaeva</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абдуллаева Луизат Муслимовна - младший научный сотрудник лаборатории редких наследственных болезней у детей Медико-генетического центра, врач-невролог отделения психоневрологии и нейрореабилитации Центра детской психоневрологии</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Luizat Muslimovna Abdullaeva - Junior Research Assistant of Laboratory of Rare Hereditary Diseases in Children of the Medical Genetic Center, Neurologist of Department of the Psychoneurology and Neurorehabilitation of Pediatric Center of Psychoneurology</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">abdullaeva.lm@nczd.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8506-2064</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурсагова</surname><given-names>Б. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Bursagova</surname><given-names>B. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бурсагова Бэлла Ибрагимовна - к. м. н., старший научный сотрудник лаборатории редких наследственных болезней у детей Медико-генетического центра, заместитель по лечебной работе отделения психоневрологии и нейрореабилитации Центра детской психоневрологии</p><p>119296, г. Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Bella Ibragimovna Bursagova - PhD (Medicine), Senior Research Associate of Laboratory of Rare Hereditary Diseases in Children of the Medical Genetic Center, Deputy for Medical Work of Department of the Psychoneurology and Neurorehabilitation of Pediatric Center of Psychoneurology</p><p>2/1, Lomonosovskij prospect, 119296, Moscow</p></bio><email xlink:type="simple">bursagova@nczd.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГАУ «НМИЦ здоровья детей» Минздрава России<country>Россия</country></aff><aff xml:lang="en">FSAI “National Medical Research Center of Children’s Health” under the Ministry of Health of Russia<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>08</day><month>01</month><year>2024</year></pub-date><volume>0</volume><issue>4</issue><fpage>31</fpage><lpage>39</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Радыгина Т.В., Петричук С.В., Курбатова О.В., Купцова Д.Г., Фисенко А.П., Семикина Е.Л., Фрейдлин Е.В., Абдуллаева Л.М., Бурсагова Б.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Радыгина Т.В., Петричук С.В., Курбатова О.В., Купцова Д.Г., Фисенко А.П., Семикина Е.Л., Фрейдлин Е.В., Абдуллаева Л.М., Бурсагова Б.И.</copyright-holder><copyright-holder xml:lang="en">Radygina T.V., Petrichuk S.V., Kurbatova O.V., Kuptsova D.G., Fisenko A.P., Semikina E.L., Freydlin E.V., Abdullaeva L.M., Bursagova B.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://adair.elpub.ru/jour/article/view/118">https://adair.elpub.ru/jour/article/view/118</self-uri><abstract><p>Рассеянный склероз (РС) — это хроническое, демиелинизирующее заболевание, приводящее к инвалидизации.Понимание этиологии РС способствует разработке патогенетических методов лечения, а поиск информативных биомаркеров эффективности лечения позволит вовремя скорректировать терапию. Целью данной работы было выявить информативные цитокины и цитокиновые профили для прогноза эффективности терапии ИНФ-β1а у детей с РС.Материалы и методы. Обследовано 66 детей с РС в возрасте 16 [14,2–17,5] лет, находящихся на терапии ИНФ-β1а: 1-я группа — пациенты в обострении РС (с активными очагами демиелинизации, по данным МРТ), n = 34; 2-я группа — пациенты в ремиссии РС (без активных очагов), n = 32. Cодержание цитокинов в сыворотке крови пациентов измеряли с помощью мультиплексной панели Human Th17 Magnetic Bead Panel.Результаты: у пациентов в обострении РС выявлено достоверное увеличение концентрации цитокинов IL5, IL6, IL9, IL12p70, IL17E/IL25, IL21, IL28A, GM-CSF, TNFβ по сравнению с детьми в ремиссии. Пороговые значения cut-off составили для IL9 (AUC = 0,785), IL6 (AUC = 0,750), TNFβ (0,740), IL28A (AUC = 0,744), выше которых можно прогнозировать у пациентов обострение РС: IL9 — 3,9 пг/мл (Sn — 70,6, Sp — 71,9), IL6 — 4,0 пг/мл (Sn — 70,6, Sp — 68,8), TNFβ — 6,6 пг/мл (Sn — 70,6, Sp — 71,9), IL28A — 243,0 пг/мл (Sn — 70,6, Sp — 71,9). Проведена оценка уровней цитокиновых профилей, ассоциированных с Т-лимфоцитами, а также с их функциями с использованием метода z-score.Выводы. Впервые продемонстрировано увеличение уровней цитокинов у детей с активными очагами демиелинизации по сравнению с пациентами, находящимися в ремиссии РС. Обнаружено увеличение провоспалительных цитокинов, ассоциированных с Th1- и Th17-, а также с Th2- и Th22-лимфоцитами. Применение пороговых значений cut-off для IL9, IL6, TNFβ, IL28A позволяет прогнозировать развитие обострения у пациентов с РС.</p></abstract><trans-abstract xml:lang="en"><p>Multiple sclerosis (MS) is a chronic, demyelinating disease that leads to disability. Understanding the etiology of MS contributes to the development of pathogenetic methods of treatment, and the search for informative biomarkers of the effectiveness of treatment will allow the patient to adjust therapy in time. The aim of this work was to determine informative cytokines and cytokine profiles to predict the effectiveness of IFN-β1a therapy in children with MS.Materials and methods. 66 children with MS aged 16 [14.2–17.5] years who are on INFß-1a therapy were examined: group 1 — patients with exacerbation of MS (with active foci of demyelination by MRI), n = 34; group 2 — patients in remission of MS (without active foci), n = 32. The content of cytokines in the blood serum of patients was assessed using the multiplex panel Human Th17 Magnetic Bead Panel.Results: There was a significant increase in cytokine concentrations in patients with exacerbation of MS compared with children in remission: IL5, IL6, IL9, IL12p70, IL17E/IL25, IL21, IL28A, GM-CSF, TNFß. Threshold values for IL9 (AUC = 0,785), IL6 (AUC = 0,750), TNFß (0,740), IL28A (AUC = 0,744) were obtained above which it is possible to predict an exacerbation of MS in patients: IL9 — 3.9 pg/ml (Sn — 70.6, Sp — 71.9), IL6 — 4.0 pg/ml (Sn — 70.6, Sp — 68.8), TNFß — 6.6 pg/ml (Sn — 70.6, Sp — 71.9), IL28A — 243.0 pg/ml (Sn — 70.6, Sp — 71.9). Cytokine profiles associated with T-lymphocytes and their functions were evaluated using z-score.Conclusions. For the first time, an increase in cytokine levels was demonstrated in children with active foci of demyelination compared to patients in remission of MS. An increase in proinflammatory cytokines and cytokine profiles associated with Th1 and Th17, as well as with Th2 and Th22 has been shown. The use of threshold values for IL9, IL6, TNFβ, IL28A will help predict the development of exacerbation in patients with MS.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>цитокины</kwd><kwd>рассеянный склероз</kwd><kwd>дети</kwd><kwd>Th1-цитокины</kwd><kwd>Th2-цитокины</kwd><kwd>Th17-цитокины</kwd><kwd>ИНФ-β1а</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cytokines</kwd><kwd>multiple sclerosis</kwd><kwd>children</kwd><kwd>Th1-cytokines</kwd><kwd>Th2-cytokines</kwd><kwd>Th17-cytokines</kwd><kwd>ИНФ-β1а</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Исследование проведено в рамках государственного задания Минздрава России, № АААА-А19-119013090093-2.</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>The study was conducted within the framework of the state assignment of the Ministry of Health of the Russian Federation, № AAAAA19-119013090093-2.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Walton C, King R, Rechtman L, Kaye W, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020; 26 (14): 1816–1821. https://doi.org/10.1177/1352458520970841.</mixed-citation><mixed-citation xml:lang="en">Walton C, King R, Rechtman L, Kaye W, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020; 26 (14): 1816–1821. https://doi.org/10.1177/1352458520970841.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бойнова ИВ, Самарина ДВ, Каторова АВ, Токарева НГ. Клинико-эпидемиологические особенности рассеянного склероза в Российской Федерации. Современные проблемы науки и образования. 2022; 5. https://science-education.ru/ru/article/view?id=32006.</mixed-citation><mixed-citation xml:lang="en">Boynova IV, Samarina DV, Katorova AV, Tokareva NG. Clinical and epidemiological features of multiple scle rosis in the Russian Federation. Sovremennye problemy nauki i obrazovanija. 2022; 5. https://science-education.ru/ru/article/ view?id=32006. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wei W, Ma D, Li L and Zhang L. Progress in the application of drugs for the treatment of multiple sclerosis. Front. Pharmacol. 2021; 12: 724718. https://doi.org/10.3389/fphar.2021.724718.</mixed-citation><mixed-citation xml:lang="en">Wei W, Ma D, Li L and Zhang L. Progress in the application of drugs for the treatment of multiple sclerosis. Front. Pharmacol. 2021; 12: 724718. https://doi.org/10.3389/fphar.2021.724718.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Куликова СЛ, Кузнецова АВ, Лихачев СА, Голец ЮН. Рассеянный склероз у детей: диагностика, лечение (обзор). Неврология и нейрохирургия. Восточная Европа. 2021; 11 (1): 69–81.</mixed-citation><mixed-citation xml:lang="en">Kulikova S, Kuzniatsova A, Likhachev S, Golets Y. Pediatric multiple sclerosis: diagnostics and treatment (Review). Neurology and Neurosurgery. Eastern Europe. 2021; 11 (1): 69–81. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Абдуллаева ЛМ, Бурсагова БИ, Куренков АЛ, Кузенкова ЛМ. Лечение рассеянного склероза у детей: обзор клинических исследований. Неврологический журнал им. Л. О. Бадаляна. 2023; 4 (1): 43–51. https://doi.org/10.46563/2686-8997-2023-4-1-43-51.</mixed-citation><mixed-citation xml:lang="en">Abdullaeva LM, Bursagova BI, Kurenkov AL, Kuzenkova LM. Treatment of multiple sclerosis in children: review of clinical trials L. O. Badalyan neurological journal. 2023; 4 (1): 43–51. https://doi.org/10.46563/2686-8997-2023-4-1-43-51. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Schreiner B, Becher B. Perspectives on cytokine-directed therapies in multiple sclerosis. Swiss Med Wkly. 2015. 145: w14199. https://doi.org/10.4414/smw.2015.14199.</mixed-citation><mixed-citation xml:lang="en">Schreiner B, Becher B. Perspectives on cytokine-directed therapies in multiple sclerosis. Swiss Med Wkly. 2015. 145: w14199. https://doi.org/10.4414/smw.2015.14199.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007: 13: 139–145. https://doi.org/10.1038/nm1551.</mixed-citation><mixed-citation xml:lang="en">Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007: 13: 139–145. https://doi.org/10.1038/nm1551.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Luchtman DW, Ellwardt E, Larochelle C, Zipp F. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments. Cytokine Growth Factor Rev. 2014; 25: 403–413. https://doi.org/10.1016/j.cytogfr.2014.07.013.</mixed-citation><mixed-citation xml:lang="en">Luchtman DW, Ellwardt E, Larochelle C, Zipp F. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments. Cytokine Growth Factor Rev. 2014; 25: 403–413. https://doi.org/10.1016/j.cytogfr.2014.07.013.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Berek K, Bauer A, Rudzki D, Auer M, et al (2023). Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum. Front. Immunol. 2023; 14: 1200146. https://doi.org/10.3389/fimmu.2023.1200146.</mixed-citation><mixed-citation xml:lang="en">Berek K, Bauer A, Rudzki D, Auer M, et al (2023). Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum. Front. Immunol. 2023; 14: 1200146. https://doi.org/10.3389/fimmu.2023.1200146.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bai Z, Chen D, Wang L, Zhao Y, et al. Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: A systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients. Front. Neurosci. 2019; 13: 1026. https://doi.org/10.3389/fnins.2019.01026.</mixed-citation><mixed-citation xml:lang="en">Bai Z, Chen D, Wang L, Zhao Y, et al. Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: A systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients. Front. Neurosci. 2019; 13: 1026. https://doi.org/10.3389/fnins.2019.01026.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Fitzner B, Hecker M, Zettl UK. Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmun. Rev. 2015; 14: 903–913. https://doi.org/10.1016/j.autrev.2015.06.001.</mixed-citation><mixed-citation xml:lang="en">Fitzner B, Hecker M, Zettl UK. Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmun. Rev. 2015; 14: 903–913. https://doi.org/10.1016/j.autrev.2015.06.001.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Salehi M, Bagherpour B, Shayghannejad V, Mohebi F, Jafari R. Th1, Th2 and Th17 cytokine profile in patients with multiple sclerosis following treatment with rapamycin. Iran. J. Immunol. 2016; IJIv13i2A7.</mixed-citation><mixed-citation xml:lang="en">Salehi M, Bagherpour B, Shayghannejad V, Mohebi F, Jafari R. Th1, Th2 and Th17 cytokine profile in patients with multiple sclerosis following treatment with rapamycin. Iran. J. Immunol. 2016; IJIv13i2A7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Martynova E, Goyal M, Johri S, Kumar V, et al. Serum and cerebrospinal fluid cytokine biomarkers for diagnosis of multiple sclerosis Hindawi Mediators of Inflammation. Volume 2020, Article ID 2727042, 10 pages. https://doi.org/10.1155/2020/2727042.</mixed-citation><mixed-citation xml:lang="en">Martynova E, Goyal M, Johri S, Kumar V, et al. Serum and cerebrospinal fluid cytokine biomarkers for diagnosis of multiple sclerosis Hindawi Mediators of Inflammation. Volume 2020, Article ID 2727042, 10 pages. https://doi.org/10.1155/2020/2727042.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cala CM, Moseley CE, Steele C, Dowdy SM, et al. T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis. Journal of neuroimmunology. 2016; 297: 1–8. https://doi.org/10.1016/j.jneuroim.2016.04.015.</mixed-citation><mixed-citation xml:lang="en">Cala CM, Moseley CE, Steele C, Dowdy SM, et al. T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis. Journal of neuroimmunology. 2016; 297: 1–8. https://doi.org/10.1016/j.jneuroim.2016.04.015.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Maes M, Carvalho AF. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. Molecular neurobiology. 2018; 55 (12): 8885–8903. https://doi.org/10.1007/s12035-018-1016-x.</mixed-citation><mixed-citation xml:lang="en">Maes M, Carvalho AF. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. Molecular neurobiology. 2018; 55 (12): 8885–8903. https://doi.org/10.1007/s12035-018-1016-x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007 Spring; 45 (2): 27–37. https://doi.org/10.1097/AIA.0b013e318034194e.</mixed-citation><mixed-citation xml:lang="en">Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007 Spring; 45 (2): 27–37. https://doi.org/10.1097/AIA.0b013e318034194e.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z, Bozec A, Ramming A, et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019; 15: 9–17. https://doi.org/10.1038/s41584-018-0109-2.</mixed-citation><mixed-citation xml:lang="en">Chen Z, Bozec A, Ramming A, et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019; 15: 9–17. https://doi.org/10.1038/s41584-018-0109-2.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cataldi C, Mari NL, Lozovoy MAB et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm Res. 2019 Jul; 68 (7): 557–567. https://doi.org/10.1007/s00011-019-01238-8.</mixed-citation><mixed-citation xml:lang="en">Cataldi C, Mari NL, Lozovoy MAB et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm Res. 2019 Jul; 68 (7): 557–567. https://doi.org/10.1007/s00011-019-01238-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson WD, Vadigepalli R. Neuroinflammation, Glia, and Cytokines: Networks of Networks. In: Jaeger D, Jung R (eds). Encyclopedia of Computational Neuroscience. Springer, New York, NY. 2022. https://doi.org/10.1007/978-1-0716-1006-0_100694.</mixed-citation><mixed-citation xml:lang="en">Anderson WD, Vadigepalli R. Neuroinflammation, Glia, and Cytokines: Networks of Networks. In: Jaeger D, Jung R (eds). Encyclopedia of Computational Neuroscience. Springer, New York, NY. 2022. https://doi.org/10.1007/978-1-0716-1006-0_100694.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Радыгина ТВ, Купцова ДГ, Курбатова ОВ, Петричук СВ, Cемикина ЕЛ, Фисенко АП, и др. Особенности показателей клеточного иммунитета в зависимости от активности очагов демиелинизации у детей с рассеянным склерозом. Медицинская иммунология. 2023; 25 (5): 1019–1026. https://doi.org/10.15789/1563-0625-FOP-2777.</mixed-citation><mixed-citation xml:lang="en">Radygina TV, Kuptsova DG, Kurbatova OV, Petrichuk SV, Semikina EL, Fisenko AP, et al. Features of parameters of cellular immune depending on the activity of foci of demyelination in children with multiple sclerosis. Medical Immunology (Russia)/Meditsinskaya Immunologiya. 2023; 25 (5): 1019–1026 (In Russ.). https://doi.org/10.15789/1563-0625-FOP-2777. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Chen W, Wang J, Yang H, Sun Y, et al. Interleukin 22 and its association with neurodegenerative disease activity. Front. Pharmacol. 2022; 13: 958022. https://doi.org/10.3389/fphar.2022.958022.</mixed-citation><mixed-citation xml:lang="en">Chen W, Wang J, Yang H, Sun Y, et al. Interleukin 22 and its association with neurodegenerative disease activity. Front. Pharmacol. 2022; 13: 958022. https://doi.org/10.3389/fphar.2022.958022.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang Q, Yang G, Xiao F, Xie J, et al. Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases. Front. Immunol. 2021; 12: 688066. https://doi:10.3389/fimmu.2021.688066.</mixed-citation><mixed-citation xml:lang="en">Jiang Q, Yang G, Xiao F, Xie J, et al. Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases. Front. Immunol. 2021; 12: 688066. https://doi:10.3389/fimmu.2021.688066.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
